Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

Executive Summary

In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.

You may also be interested in...



Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer

FDA granted Opdivo an ultra-rapid approval for the treatment of classical Hodgkin lymphoma that has relapsed or progressed, making it the first PD-1 inhibitor approved for hematological cancer.

Celgene Diversifying Beyond Myeloma Backbone Revlimid

Promising pipeline will continue to deliver as Revlimid matures.

Multiple Myeloma Market Snapshot: New Drugs And Big Changes

The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel